Literature DB >> 2766678

Variability in muscle fibre areas in whole human quadriceps muscle: how to reduce sampling errors in biopsy techniques.

J Lexell1, C C Taylor.   

Abstract

A single biopsy is a poor estimator of the muscle fibre cross-sectional area (CSA) for a whole human muscle because of the large variability in the fibre area within a muscle. To determine how the sampling errors in biopsy techniques can be reduced, data on the CSA of type 1 and type 2 fibres obtained from cross-sections of whole vastus lateralis muscle of young men, have been analysed statistically. To obtain a good estimate of the mean fibre CSA in a biopsy, measuring all fibres in that biopsy gives the best result. To obtain a good estimate of the mean fibre CSA for a whole muscle, the number of biopsies has a much greater influence on the sampling error than the number of fibres measured in each biopsy, but the number of biopsies needed to obtain a given sampling error can vary by a factor of two. If the fibre CSA in three or more biopsies is measured, it is sufficient to measure only 25 fibres in each biopsy. If less than three biopsies are taken, there is no worthwhile reduction in sampling error when more than 100 fibres are measured. To determine the mean fibre CSA for a whole group of individuals, our preference is to maximize the number of individuals, and only take single biopsies. In conclusion, to determine the mean fibre CSA for this particular muscle with a certain precision, we suggest analysis of three biopsies, taken from different depths of the muscle, and measurement of 25 fibres in each biopsy.

Entities:  

Mesh:

Year:  1989        PMID: 2766678     DOI: 10.1111/j.1475-097x.1989.tb00987.x

Source DB:  PubMed          Journal:  Clin Physiol        ISSN: 0144-5979


  7 in total

1.  Fibre type composition of the human psoas major muscle with regard to the level of its origin.

Authors:  Juraj Arbanas; Gordana Starcevic Klasan; Marina Nikolic; Romana Jerkovic; Ivo Miljanovic; Daniela Malnar
Journal:  J Anat       Date:  2009-12       Impact factor: 2.610

2.  The interplay of central and peripheral factors in limiting maximal O2 consumption in man after prolonged bed rest.

Authors:  G Ferretti; G Antonutto; C Denis; H Hoppeler; A E Minetti; M V Narici; D Desplanches
Journal:  J Physiol       Date:  1997-06-15       Impact factor: 5.182

3.  Molecular biomarkers monitoring human skeletal muscle fibres and microvasculature following long-term bed rest with and without countermeasures.

Authors:  M Salanova; G Schiffl; B Püttmann; B G Schoser; D Blottner
Journal:  J Anat       Date:  2008-01-21       Impact factor: 2.610

4.  Multiple sclerosis affects skeletal muscle characteristics.

Authors:  Inez Wens; Ulrik Dalgas; Frank Vandenabeele; Maartje Krekels; Lotte Grevendonk; Bert O Eijnde
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

5.  Six Weeks of Low-Load Blood Flow Restricted and High-Load Resistance Exercise Training Produce Similar Increases in Cumulative Myofibrillar Protein Synthesis and Ribosomal Biogenesis in Healthy Males.

Authors:  Peter Sieljacks; Jakob Wang; Thomas Groennebaek; Emil Rindom; Jesper Emil Jakobsgaard; Jon Herskind; Anders Gravholt; Andreas B Møller; Robert V Musci; Frank V de Paoli; Karyn L Hamilton; Benjamin F Miller; Kristian Vissing
Journal:  Front Physiol       Date:  2019-05-29       Impact factor: 4.566

6.  Microbiopsy Sampling for Examining Age-Related Differences in Skeletal Muscle Fiber Morphology and Composition.

Authors:  Garrett M Hester; Trisha A VanDusseldorp; Phuong L Ha; Kaveh Kiani; Alex A Olmos; Melody Jabbari; Shania Kalladanthyil; SooBin An; Alyssa R Bailly; Benjamin E Dalton; Anton L Bryantsev
Journal:  Front Physiol       Date:  2022-01-10       Impact factor: 4.566

7.  High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise Capacity, a Randomised Controlled Trial.

Authors:  Inez Wens; Ulrik Dalgas; Frank Vandenabeele; Lotte Grevendonk; Kenneth Verboven; Dominique Hansen; Bert O Eijnde
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.